Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2008

01.11.2008 | Epidemiology

Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density

verfasst von: Martijn Verheus, James D. McKay, Rudolf Kaaks, Federico Canzian, Carine Biessy, Mattias Johansson, Diederick E. Grobbee, Petra H. M. Peeters, Carla H. van Gils

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction High breast density is one of the strongest known risk factors for developing breast cancer. Insulin-like growth factor I (IGF-I) is a strong mitogen and has been suggested to increase breast cancer risk by increasing the amount of dense tissue in the female breast. Objectives We wanted to investigate the effect of common variation in the IGF-1 gene on serum IGF-I levels and on breast density. Design and methods Mammograms and blood samples of 1,928 premenopausal participants of the Dutch Prospect-EPIC cohort were collected at baseline. Using a haplotype tagging approach, 16 single nucleotide polymorphisms (SNP) from three blocks covering the IGF-1 gene were genotyped in all study participants. Breast density was assessed using a quantitative computer-assisted method. For a subgroup of women, who went through menopause within 5 years after recruitment (n = 656), premenopausal IGF-I levels and additionally postmenopausal breast density were determined. False positive report probabilities (FPRP) for statistically significant relations were calculated using the Wacholder method. Results The minor alleles of five SNPs in block 3 were significantly associated with elevated levels of IGF-I (rs9989002, rs2033178, rs7136446, rs978458, rs6220; P-values: 0.01–0.04). The same SNPs were related with modestly higher percent breast density before menopause and—in the subgroup of women that became postmenopausal during follow-up—with a modestly higher percent breast density after menopause. The most significant result, i.e. the relation between rs6220 and IGF-I levels, had an FPRP  <0.5 assuming prior probabilities of 0.01 and higher. Conclusion Common genetic variation in the IGF-1 gene is related to circulating levels of IGF-I, but the relationship with breast density is indecisive.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Lee AV, Yee D (1995) Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415–421PubMedCrossRef Lee AV, Yee D (1995) Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415–421PubMedCrossRef
3.
Zurück zum Zitat Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRef Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRef
4.
Zurück zum Zitat Toniolo P, Bruning PF, Akhmedkhanov A et al (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828–832PubMedCrossRef Toniolo P, Bruning PF, Akhmedkhanov A et al (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828–832PubMedCrossRef
5.
Zurück zum Zitat Krajcik RA, Borofsky ND, Massardo S et al (2002) Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566–1573PubMed Krajcik RA, Borofsky ND, Massardo S et al (2002) Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566–1573PubMed
6.
Zurück zum Zitat Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed
7.
Zurück zum Zitat Allen NE, Roddam AW, Allen DS et al (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92:1283–1287PubMedCrossRef Allen NE, Roddam AW, Allen DS et al (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92:1283–1287PubMedCrossRef
8.
Zurück zum Zitat Schernhammer ES, Holly JM, Pollak MN et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699–704PubMedCrossRef Schernhammer ES, Holly JM, Pollak MN et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699–704PubMedCrossRef
9.
Zurück zum Zitat Kaaks R, Lundin E, Rinaldi S et al (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13:307–316PubMedCrossRef Kaaks R, Lundin E, Rinaldi S et al (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13:307–316PubMedCrossRef
10.
Zurück zum Zitat Rinaldi S, Peeters PH, Berrino F et al (2006) IGF-I, IGFBP-3 and breast cancer risk in women: the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 13:593–605PubMedCrossRef Rinaldi S, Peeters PH, Berrino F et al (2006) IGF-I, IGFBP-3 and breast cancer risk in women: the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 13:593–605PubMedCrossRef
11.
Zurück zum Zitat Schernhammer ES, Holly JM, Hunter DJ et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13:583–592PubMedCrossRef Schernhammer ES, Holly JM, Hunter DJ et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13:583–592PubMedCrossRef
12.
Zurück zum Zitat Keinan-Boker L, Bueno De Mesquita HB, Kaaks R et al (2003) Circulating levels of insulin-like growth factor I, its binding proteins-1,-2,-3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106:90–95PubMedCrossRef Keinan-Boker L, Bueno De Mesquita HB, Kaaks R et al (2003) Circulating levels of insulin-like growth factor I, its binding proteins-1,-2,-3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106:90–95PubMedCrossRef
13.
Zurück zum Zitat Gronbaek H, Flyvbjerg A, Mellemkjaer L et al (2004) Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13:1759–1764PubMed Gronbaek H, Flyvbjerg A, Mellemkjaer L et al (2004) Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13:1759–1764PubMed
14.
Zurück zum Zitat Byrne C, Colditz GA, Willett WC et al (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744–3748PubMed Byrne C, Colditz GA, Willett WC et al (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744–3748PubMed
15.
Zurück zum Zitat Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991–996PubMedCrossRef Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991–996PubMedCrossRef
16.
Zurück zum Zitat Diorio C, Pollak M, Byrne C et al (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065–1073PubMedCrossRef Diorio C, Pollak M, Byrne C et al (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065–1073PubMedCrossRef
17.
Zurück zum Zitat Boyd NF, Stone J, Martin LJ et al (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876–882PubMedCrossRef Boyd NF, Stone J, Martin LJ et al (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876–882PubMedCrossRef
18.
Zurück zum Zitat Lai JH, Vesprini D, Zhang W et al (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573–582PubMed Lai JH, Vesprini D, Zhang W et al (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573–582PubMed
19.
Zurück zum Zitat dos Santos Silva I, Johnson N, De Stavola B et al (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:449–455PubMedCrossRef dos Santos Silva I, Johnson N, De Stavola B et al (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:449–455PubMedCrossRef
20.
Zurück zum Zitat Verheus M, Peeters PH, Kaaks R et al (2007) Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause. Cancer Epidemiol Biomarkers Prev 16:451–457PubMedCrossRef Verheus M, Peeters PH, Kaaks R et al (2007) Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause. Cancer Epidemiol Biomarkers Prev 16:451–457PubMedCrossRef
21.
Zurück zum Zitat Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 145:970–976PubMed Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 145:970–976PubMed
22.
Zurück zum Zitat Rollison DE, Newschaffer CJ, Tao Y et al (2006) Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 118:1279–1284PubMedCrossRef Rollison DE, Newschaffer CJ, Tao Y et al (2006) Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 118:1279–1284PubMedCrossRef
23.
Zurück zum Zitat Tamimi RM, Cox DG, Kraft P et al (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18PubMedCrossRef Tamimi RM, Cox DG, Kraft P et al (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18PubMedCrossRef
24.
Zurück zum Zitat Riboli E, Kaaks R (1997) The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26 Suppl 1:S6–S14PubMedCrossRef Riboli E, Kaaks R (1997) The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26 Suppl 1:S6–S14PubMedCrossRef
25.
Zurück zum Zitat Riboli E, Hunt KJ, Slimani N et al (2002) European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124PubMedCrossRef Riboli E, Hunt KJ, Slimani N et al (2002) European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124PubMedCrossRef
26.
Zurück zum Zitat Boker LK, Van Noord PA, van der Schouw YT et al (2001) Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European prospective investigation into cancer and nutrition. Eur J Epidemiol 17:1047–1053PubMedCrossRef Boker LK, Van Noord PA, van der Schouw YT et al (2001) Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European prospective investigation into cancer and nutrition. Eur J Epidemiol 17:1047–1053PubMedCrossRef
27.
Zurück zum Zitat Johansson M, McKay JD, Stattin P et al (2007) Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer 120:539–542PubMedCrossRef Johansson M, McKay JD, Stattin P et al (2007) Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer 120:539–542PubMedCrossRef
28.
Zurück zum Zitat Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef
29.
Zurück zum Zitat Stram DO, Haiman CA, Hirschhorn JN et al (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55:27–36PubMedCrossRef Stram DO, Haiman CA, Hirschhorn JN et al (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55:27–36PubMedCrossRef
30.
Zurück zum Zitat Al Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10PubMedCrossRef Al Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10PubMedCrossRef
31.
Zurück zum Zitat Cheng I, Stram DO, Penney KL et al (2006) Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst 98:123–134PubMed Cheng I, Stram DO, Penney KL et al (2006) Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst 98:123–134PubMed
32.
Zurück zum Zitat Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921–927PubMed Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921–927PubMed
33.
Zurück zum Zitat Stram DO, Leigh PC, Bretsky P et al (2003) Modeling and E–M estimation of haplotype-specific relative risks from genotype data for a case–control study of unrelated individuals. Hum Hered 55:179–190PubMedCrossRef Stram DO, Leigh PC, Bretsky P et al (2003) Modeling and E–M estimation of haplotype-specific relative risks from genotype data for a case–control study of unrelated individuals. Hum Hered 55:179–190PubMedCrossRef
34.
Zurück zum Zitat Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307PubMedCrossRef Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307PubMedCrossRef
35.
Zurück zum Zitat van Duijnhoven FJ, Peeters PH, Warren RM et al (2006) Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density. Cancer Epidemiol Biomarkers Prev 15:462–467PubMedCrossRef van Duijnhoven FJ, Peeters PH, Warren RM et al (2006) Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density. Cancer Epidemiol Biomarkers Prev 15:462–467PubMedCrossRef
36.
Zurück zum Zitat Wacholder S, Chanock S, Garcia-Closas M et al (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedCrossRef Wacholder S, Chanock S, Garcia-Closas M et al (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedCrossRef
37.
Zurück zum Zitat Katan MB (2004) Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986 i:507–508; Int J Epidemiol 33:9 Katan MB (2004) Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986 i:507–508; Int J Epidemiol 33:9
38.
Zurück zum Zitat Smith GD, Ebrahim S (2004) Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33:30–42PubMedCrossRef Smith GD, Ebrahim S (2004) Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33:30–42PubMedCrossRef
39.
Zurück zum Zitat Johansson M, McKay JD, Wiklund F et al (2007) Implications for prostate cancer of IGF1 genetic variation and circulating IGF1 levels. J Clin Endocrinol Metab. doi:10.1210/jc.2007-0887 PubMed Johansson M, McKay JD, Wiklund F et al (2007) Implications for prostate cancer of IGF1 genetic variation and circulating IGF1 levels. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2007-0887 PubMed
40.
Zurück zum Zitat Setiawan VW, Cheng I, Stram DO et al (2006) Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:172–174PubMedCrossRef Setiawan VW, Cheng I, Stram DO et al (2006) Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:172–174PubMedCrossRef
41.
Zurück zum Zitat Hong Y, Pedersen NL, Brismar K et al (1996) Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81:1791–1797PubMedCrossRef Hong Y, Pedersen NL, Brismar K et al (1996) Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81:1791–1797PubMedCrossRef
42.
Zurück zum Zitat Harrela M, Koistinen H, Kaprio J et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612–2615PubMedCrossRef Harrela M, Koistinen H, Kaprio J et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612–2615PubMedCrossRef
Metadaten
Titel
Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density
verfasst von
Martijn Verheus
James D. McKay
Rudolf Kaaks
Federico Canzian
Carine Biessy
Mattias Johansson
Diederick E. Grobbee
Petra H. M. Peeters
Carla H. van Gils
Publikationsdatum
01.11.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9827-x

Weitere Artikel der Ausgabe 1/2008

Breast Cancer Research and Treatment 1/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.